Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose of this study is to treat glucocorticoid induced hyperglycemia due to glucocorticoid pulse therapy in a efficacious, safe and convenient way. Patients with acute exacerbation of COPD treated with glucocorticoid pulse therapy and at high risk for glucocorticoid induced hyperglycemia (defined as known type 2 DM or glucose \> 10mmol/l at admission) will be randomized to treatment of dapagliflozin or placebo orally, once daily.

Percentage of time within glucose target range (3,9-10 mmol/l) and incidence rate of hypoglycemia will be compared between dapagliflozin group and placebo group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

NCT00673231

Type 2 Diabetes

COMPLETED PHASE3

Evaluation of Dapagliflozin Taken Twice-daily

NCT01217892

Type 2 Diabetes

COMPLETED PHASE3

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

NCT01042977

Type 2 Diabetes Mellitus Cardiovascular Disease Inadequate Glycaemic Control

COMPLETED PHASE3

The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes

NCT04219124

Type 2 Diabetes

COMPLETED PHASE4

Effect of Dapagliflozin on Glycemic Variability

NCT02459353

Type 2 Diabetes Mellitus

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale: Patients hospitalized for COPD exacerbation treated with high dose glucocorticoids, frequently develop hyperglycaemia. Currently, sliding scale insulin is often used to bridge such episodes. However, sliding scale insulin is patient unfriendly, does not reduce glycaemic excursion nor glycaemic variability. In contrast, pharmacologic inhibition of the sodium glucose transporter-2 (SGLT-2) can be given as an oral agent and is likely to result in better glucose control with lower risk of hypoglycaemia Objective: glucose control and safety (risk of hypoglycaemia). Secondary objectives are patient satisfaction, other safety outcomes and other parameters of glucose control Study design: Double-blind placebo controlled intervention study Study population: Patients hospitalized for an exacerbation of chronic obstructive lung disease who are treated with high dose glucocorticoids.

Intervention: One group receives once daily a 10mg tablet of dapagliflozin and the other group receives once daily a placebo tablet as add on to their prestudy glucose-lowering medication. Both groups will be treated with glucose lowering escape medication if required.

Main study parameters/endpoints: Glucose control is measured as the average time spent within target range in each patient. Safety is measured as the incidence rate of hypoglycaemia during study follow-up.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The burden of participation consists of the extra capillary glucose measurements that will be done 3-4 times daily and wearing a coin size glucose sensor. Furthermore, patients have to fill out a treatment satisfaction questionnaire. There will be no extra site visits for participants.

Dapagliflozin (experimental group) carries a risk of hypoglycaemia, especially for patient who have concomitant therapy with insulin or sulfonylurea derivatives. Patients will be instructed to anticipate, and if required dosing of glucose lowering therapy will be adjusted. Furthermore, dapagliflozin carries an increased risk of urogenital infections, increased haematocrit and LDL cholesterol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperglycemia Steroid-induced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dapagliflozin + sliding scale insulin.

Treatment with dapagliflozin 10mg once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels \> 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.

Group Type EXPERIMENTAL

Dapagliflozin

Intervention Type DRUG

Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD

Sliding scale insulin

Intervention Type DRUG

Sliding scale insulin with short acting insulin based on current glucose levels

Placebo + sliding scale insulin

Treatment with placebo once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels \> 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.

Group Type PLACEBO_COMPARATOR

Sliding scale insulin

Intervention Type DRUG

Sliding scale insulin with short acting insulin based on current glucose levels

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dapagliflozin

Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD

Intervention Type DRUG

Sliding scale insulin

Sliding scale insulin with short acting insulin based on current glucose levels

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Forxiga Supplemental insulin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent
* Hospitalization due to AECOPD
* Treatment with ≥30mg prednisone daily or equivalent dose of glucocorticoid for AECOPD
* An expected duration of glucocorticoid treatment of 3-14 days at study entry
* Known type 2 diabetes or glucose ≥ 10 mmol/l at admission

Exclusion Criteria

* High dose glucocorticoid treatment started ≥7 days before study entry
* Need for ICU admission
* Chronic kidney disease stage G3 (glomerular filtration rate \<60ml/minute)
* Recurrent genital or urinary tract infection
* Current use of any SGLT-2 inhibiting agent
* Suspected volume depletion
* Congestive heart failure functional classification NYHA class IV/IV or instable heart failure
* Acute stroke within 2 months before inclusion.
* Recent cardiovascular event: acute coronary syndrome, hospitalisation for unstable angina or coronary revascularisation within 2 months before inclusion
* Suspected liver disease, confirmed by AST/ALT \> 3x ULN or bilirubin \>2.0mg/dl (34.2 μmol/l) or serologically proven infection with hepatitis B or hepatitis C
* Pregnancy or breast feeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No